Ac t i o n | 28 Jul 2026 00:00:00 ET │ 17 pages AstraZeneca PLC (AZN.L) Pipeline still looks full. Raising EPS 1-3% and TP to £178 CITI'S TAKE AZN's 2Q results looked solid to us, with the call a good reminder of the size and breadth of its pipeline, with 19 key Phase III readouts expected in 2027 and AZN flagging 12 assets with peak sales potential >$5bn and 5 with peak potential $3-5bn expected to have pivotal readouts by 2030 and drive growth beyond. In our view, this underscores its ability to absorb se ...